Home/Filings/4/0001641172-25-018489
4//SEC Filing

Pursglove Geordan Garrett 4

Accession 0001641172-25-018489

CIK 0001335105other

Filed

Jul 8, 8:00 PM ET

Accepted

Jul 9, 6:37 PM ET

Size

5.7 KB

Accession

0001641172-25-018489

Insider Transaction Report

Form 4
Period: 2025-07-03
Pursglove Geordan Garrett
DirectorCEO and Chairman of the Board
Transactions
  • Award

    Options to Purchase Common Stock

    2025-07-03+350,000350,000 total
    Exercise: $2.83From: 2025-07-03Exp: 2030-07-03Common (350,000 underlying)
Footnotes (1)
  • [F1]Effective July 3, 2025, the reporting person was granted stock options to purchase an aggregate of 350,000 shares vesting 50% on the effective date, 25% on September 30,2025 and 25% on December 31,2025. The grant was a signing bonus for the reporting person entering into an employment agreement with the issuer. The exercise price is $2.83 per share.

Documents

1 file

Issuer

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

CIK 0001335105

Entity typeother

Related Parties

1
  • filerCIK 0002073519

Filing Metadata

Form type
4
Filed
Jul 8, 8:00 PM ET
Accepted
Jul 9, 6:37 PM ET
Size
5.7 KB